HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Ebrahem, Q. Articles by Sears, J. E. Search for Related Content PubMed PubMed Citation Articles by Ebrahem, Q. Articles by Sears, J. E.

Triamcinolone Acetonide Inhibits IL-6– and VEGF-Induced Angiogenesis Downstream of the IL-6 and VEGF Receptors

¹From the Cole Eye Institute and the ³Department of Cell Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio; and the ²Department of Ophthalmology, Hiroshima University, Hiroshima, Japan.

PURPOSE. To test whether triamcinolone acetonide (TA) inhibits angiogenesis induced by IL-6 or VEGF and whether this inhibition is through antagonism of the IL-6 or the VEGF receptor 2.

METHODS. A rat cornea micropocket assay was used to initiate IL-6– and VEGF-mediated angiogenesis. The ability of TA or neutralizing VEGF antibody to inhibit IL-6– or VEGF-mediated neovascularization was analyzed by measuring vessel length, vessel extension, and vessel area. The phosphorylation of signal transduction activator 3 (STAT3), VEGF receptor, and extracellular signal-regulated kinase 1/2 (ERK1/2) was determined by Western blot in human umbilical vein endothelial cell (HUVEC) lysates after stimulus with IL-6 or VEGF, with and without TA pretreatment. The effect of IL-6 or TA on STAT3 expression in cornea was determined by Western blot.

RESULTS. IL-6 induced corneal angiogenesis in a dose-dependent manner, with 350 ng producing a peak at day 6. VEGF antibodies and TA blocked IL-6-mediated limbal neovascularization. TA also directly inhibited angiogenesis stimulated by a VEGF pellet; the glucocorticoid receptor antagonist mifepristone neutralized TA inhibition of angiogenesis. TA did not inhibit IL-6-induced STAT3 phosphorylation and did not inhibit VEGF-induced phosphorylation of the VEGF receptor 2 or of ERK1/2 in endothelial cells, but TA decreased IL-6-induced STAT3 expression in cornea.

CONCLUSIONS. IL-6– and VEGF-mediated corneal neovascularization are blocked by TA through the mifepristone-sensitive steroid receptor. TA inhibits IL-6-induced STAT3 expression in cornea, but it does not inhibit activation of the IL-6 or the VEGF receptor in cultured human endothelial cells. This finding has two implications. The fact that TA directly inhibits VEGF action implies that other factors may be critical to angiogenesis and sensitive to glucocorticoids.

This article has been cited by other articles:

				D. Y. Chong, C. S. Boehlke, Q.-D. Zheng, L. Zhang, Y. Han, and D. N. Zacks Interleukin-6 as a Photoreceptor Neuroprotectant in an Experimental Model of Retinal Detachment Invest. Ophthalmol. Vis. Sci., July 1, 2008; 49(7): 3193 - 3200. [Abstract] [Full Text] [PDF]